JP2024500946A5 - - Google Patents
Info
- Publication number
- JP2024500946A5 JP2024500946A5 JP2023538767A JP2023538767A JP2024500946A5 JP 2024500946 A5 JP2024500946 A5 JP 2024500946A5 JP 2023538767 A JP2023538767 A JP 2023538767A JP 2023538767 A JP2023538767 A JP 2023538767A JP 2024500946 A5 JP2024500946 A5 JP 2024500946A5
- Authority
- JP
- Japan
- Prior art keywords
- nanobody
- antigen
- binding fragment
- thrombosis
- gpvi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020602.5A GB202020602D0 (en) | 2020-12-24 | 2020-12-24 | Nanobody |
| GB2020602.5 | 2020-12-24 | ||
| PCT/EP2021/087129 WO2022136457A1 (en) | 2020-12-24 | 2021-12-21 | Nanobody to glycoprotein vi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500946A JP2024500946A (ja) | 2024-01-10 |
| JP2024500946A5 true JP2024500946A5 (cg-RX-API-DMAC7.html) | 2024-11-06 |
Family
ID=74532190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538767A Pending JP2024500946A (ja) | 2020-12-24 | 2021-12-21 | 糖タンパク質viに対するナノボディ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240067721A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267624A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500946A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117043191A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203202A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202020602D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022136457A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026019685A1 (en) * | 2024-07-17 | 2026-01-22 | Harpoon Therapeutics, Inc. | Her2 targeting trispecific protein for treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130543D0 (en) * | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| US20090130021A1 (en) * | 2002-06-07 | 2009-05-21 | Gotz Munch | Methods, products and uses involving platelets and/or the vasculature |
| WO2007091719A1 (ja) * | 2006-02-07 | 2007-08-16 | Mochida Pharmaceutical Co., Ltd. | 抗gpvi抗体の併用療法及び新規医薬用途 |
| EP1916259A1 (en) * | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| JP5843783B2 (ja) * | 2009-12-18 | 2016-01-13 | サノフイ | GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用 |
-
2020
- 2020-12-24 GB GBGB2020602.5A patent/GB202020602D0/en not_active Ceased
-
2021
- 2021-12-21 WO PCT/EP2021/087129 patent/WO2022136457A1/en not_active Ceased
- 2021-12-21 CN CN202180094483.4A patent/CN117043191A/zh active Pending
- 2021-12-21 US US18/269,308 patent/US20240067721A1/en active Pending
- 2021-12-21 EP EP21844966.8A patent/EP4267624A1/en active Pending
- 2021-12-21 JP JP2023538767A patent/JP2024500946A/ja active Pending
- 2021-12-21 CA CA3203202A patent/CA3203202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis | |
| Hohmann et al. | Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? | |
| JP6033781B2 (ja) | 低分子ペプチド阻害剤によるCD40L/Mac−1相互作用の選択的ターゲティングならびに炎症およびアテローム形成の治療のためのその使用 | |
| CA2916399C (en) | Combination therapy using a factor xii inhibitor and a c1-inhibitor | |
| Navarro et al. | The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice | |
| US9365650B2 (en) | Single chain antibodies that specifically bind to the activated state of the platelet integrin receptor GP IIb/IIIa | |
| JP2005510719A (ja) | 新規自己集合分子 | |
| NZ540771A (en) | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen | |
| TWI786485B (zh) | 抗血小板膜糖蛋白ib alpha人源化抗體及其應用 | |
| US20210179717A1 (en) | Antibodies against mac-1 | |
| AU2002352438B2 (en) | Human antibodies against human glycoprotein VI and their use | |
| US20110045008A1 (en) | Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders | |
| TW201728603A (zh) | 凝血酶抗體、其抗原結合片段及醫藥用途 | |
| JP7839117B2 (ja) | 抗プロテインsシングルドメイン抗体及びそれを含むポリペプチド | |
| Qian et al. | Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library | |
| JP2024500946A (ja) | 糖タンパク質viに対するナノボディ | |
| UA64693C2 (en) | Novel staphylokinase derivatives, a method for the preparation thereof and pharmaceutical composition | |
| Maurice et al. | Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse | |
| US20090311267A1 (en) | Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks | |
| CN109157654B (zh) | Tmx1的用途 | |
| WO2020243228A1 (en) | Antibodies to polyphosphate decrease fibrosis | |
| US20250051452A1 (en) | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering | |
| Zhu et al. | Generation and characterization of a recombinant single chain Fv antibody to von Willebrand factor A1 domain from phage display library | |
| JP2026509897A (ja) | 抗gpvi抗体及びその機能的断片 | |
| Lee et al. | Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy |